Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01896479) enrolled 247 people in total — 123 in a group taking a 60 mg daily dose of a drug called cabozantinib, and 124 in a group taking a 140 mg daily dose of the same drug. All participants received at least one dose. The trial was primarily measuring how long participants went without their disease getting worse (called "progression-free survival"), and also looked at how many participants' tumours shrank or disappeared by a meaningful amount (called the "objective response rate"). The reported data shows that, when assessed by an independent reviewing committee, the median time before disease progression or death was 11 months in the 60 mg group and 13.9 months in the 140 mg group. "Median" here simply means the midpoint — half the participants in each group reached that point before that time, and half after it. Participants were followed for up to around 31 months. For the secondary measure — the proportion of participants whose tumours shrank or disappeared to a qualifying degree — the reported data shows 33% in the 60 mg group and 33% in the 140 mg group, meaning roughly one in three participants in each group met that measurement threshold. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35403447) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Thyroid Cancer Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with medullary thyroid cancer (MTC), confirmed by a lab test on a tissue sample.
- You have been tested (or are willing to be tested) for a specific genetic change called a RET mutation, using a tumor sample.
- You have cancer that has spread to other parts of the body and can be measured on a scan (CT, MRI, PET, bone scan, or X-ray) taken within 28 days before joining the trial.
- Your scans show that the cancer has gotten worse compared to earlier scans taken within the past 14 months.
- Any side effects from previous cancer treatments have mostly gone away or are mild and stable.
- You are generally well enough to carry out daily activities with little to no limitation (confirm with trial site for exact fitness level required).
- Your blood tests show that your organs (such as kidneys, liver, and bone marrow) are working well enough to participate.
- You are able to understand what the trial involves and have signed a consent form agreeing to take part.
- If you are sexually active and able to have children, you and your partner agree to use reliable contraception during the trial and for 4 months after the last dose of treatment.
Who may not be able to join:
- You have previously been treated with the study drug, cabozantinib.
- You have taken certain targeted cancer medicines or hormonal therapy recently (within about 28 days or a specific number of half-lives of the drug, whichever is shorter).
- You have received any systemic (whole-body) cancer treatment within the past 28 days (or 42 days for certain chemotherapy drugs).
- You have taken part in another clinical trial involving an experimental medicine within the past 28 days.
- You have had radiation therapy within the past 28 days (or 14 days if it was radiation to the bones), or a radioactive treatment within the past 42 days, or you are still experiencing significant problems from past radiation.
- You have cancer that has spread to the brain or spinal cord that is untreated or still causing active symptoms requiring medication.
- You are currently taking blood-thinning medicines (such as warfarin) or medicines that reduce blood clotting (such as clopidogrel) at full treatment doses.
- You have serious uncontrolled health conditions, such as heart problems, digestive issues, active infections, wounds that are not healing, or have had recent surgery.
- A recent heart test (ECG) shows an abnormal result in a specific measurement of heart rhythm (confirm with trial site).
- You are unable to swallow multiple tablets or capsules.
- You have a known allergy to any ingredient in the study treatment.
- You are currently pregnant or breastfeeding.
- You have been diagnosed with another type of cancer within the past 2 years (with some exceptions, such as certain minor skin cancers or low-grade cancers that were fully treated without systemic therapy).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression Free Survival (PFS) Per Blinded Independent Radiology Committee (BIRC) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.